Mu-type opioid receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Mu-type opioid receptor as ChEMBL target CHEMBL4354, mapped to UniProt P97266. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Mu-type opioid receptor matters
Mu-type opioid receptor is reviewed as Mu-type opioid receptor (UniProt P97266); the current evidence base includes 21 approved drugs, 2376 compounds, and 692 assays, with lead potency reaching pChEMBL 11.0.
Mu-type opioid receptor Sequence length is 98 aa.
Review this target as Mu-type opioid receptor, mapped to UniProt P97266. Sequence length is 98 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 21 approved drugs, 2376 compounds, and 692 assays for this target. The dominant activity type is IC50. CHEMBL2113675 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL2113675 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Mu-type opioid receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P97266, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2113675
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL52451
|
10.9 | Ki | — |
|
|
No preferred name
CHEMBL290429
|
10.7 | IC50 | Clinical |
|
|
No preferred name
CHEMBL300662
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL50594
|
10.6 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
NALFURAFINE
CHEMBL267495
|
2009 |
|
|
NALFURAFINE HYDROCHLORIDE
CHEMBL490665
|
2009 |
|
|
LEVORPHANOL
CHEMBL592
|
1991 |
|
|
ALFENTANIL
CHEMBL634
|
1986 |
|
|
NALTREXONE
CHEMBL19019
|
1984 |
|
|
MORPHINE
CHEMBL70
|
1984 |
|
|
BUPRENORPHINE
CHEMBL511142
|
1981 |
|
|
LOPERAMIDE
CHEMBL841
|
1976 |
|
|
NALOXONE
CHEMBL80
|
1971 |
|
|
FENTANYL CITRATE
CHEMBL688
|
1968 |
|
|
FENTANYL
CHEMBL596
|
1968 |
|
|
OXYMORPHONE
CHEMBL963
|
1959 |
|
|
MEPERIDINE
CHEMBL607
|
1942 |